Cortexyme Stock Forecast, Price & News

Cortexyme (NASDAQ:CRTX) Frequently Asked Questions

Is Cortexyme a buy right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cortexyme in the last year. There are currently 2 sell ratings, 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Cortexyme stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRTX, but not buy additional shares or sell existing shares.
View analyst ratings for Cortexyme or view top-rated stocks.

How has Cortexyme's stock price been impacted by COVID-19?

Cortexyme's stock was trading at $37.02 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CRTX stock has decreased by 67.5% and is now trading at $12.03.
View which stocks have been most impacted by COVID-19.

Are investors shorting Cortexyme?

Cortexyme saw a increase in short interest in the month of October. As of October 29th, there was short interest totaling 7,940,000 shares, an increase of 207.8% from the October 14th total of 2,580,000 shares. Based on an average daily volume of 1,520,000 shares, the days-to-cover ratio is currently 5.2 days. Currently, 53.0% of the shares of the company are sold short.
View Cortexyme's Short Interest.

When is Cortexyme's next earnings date?

Cortexyme is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for Cortexyme.

How were Cortexyme's earnings last quarter?

Cortexyme, Inc. (NASDAQ:CRTX) released its quarterly earnings results on Friday, October, 29th. The biopharmaceutical company reported ($0.73) earnings per share for the quarter, meeting the Zacks' consensus estimate of ($0.73).
View Cortexyme's earnings history.

What price target have analysts set for CRTX?

6 Wall Street analysts have issued twelve-month price targets for Cortexyme's shares. Their forecasts range from $15.00 to $75.00. On average, they anticipate Cortexyme's share price to reach $38.50 in the next twelve months. This suggests a possible upside of 220.0% from the stock's current price.
View analysts' price targets for Cortexyme or view top-rated stocks among Wall Street analysts.

Who are Cortexyme's key executives?

Cortexyme's management team includes the following people:

• Casey Crawford Lynch, Chairman, President & Chief Executive Officer
• Christopher P. Lowe, Chief Operating & Financial Officer (LinkedIn Profile)
• Stephen S. Dominy, Chief Scientific Officer & Director (LinkedIn Profile)
• Leslie J. Holsinger, Executive Vice President-Research & Development
• Michael J. Detke, Chief Medical Officer (LinkedIn Profile)

Who are some of Cortexyme's key competitors?

Some companies that are related to Cortexyme include Cerner (CERN), Omnicell (OMCL), Vocera Communications (VCRA), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Computer Programs and Systems (CPSI), Athena Technology Acquisition (ATHN) and Mirage Energy (MRGE).
View all of CRTX's competitors.

What other stocks do shareholders of Cortexyme own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cortexyme investors own include ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), DHT (DHT), EnLink Midstream (ENLC), Golar LNG Partners (GMLP), Matinas BioPharma (MTNB), OrganiGram (OGI), Pennsylvania Real Estate Investment Trust (PEI) and Tilly's (TLYS).

When did Cortexyme IPO?

(CRTX) raised $75 million in an initial public offering (IPO) on Thursday, May 9th 2019. The company issued 4,400,000 shares at $16.00-$18.00 per share. BofA Merrill Lynch and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity and JMP Securities were co-managers.

What is Cortexyme's stock symbol?

Cortexyme trades on the NASDAQ under the ticker symbol "CRTX."

Who are Cortexyme's major shareholders?

Cortexyme's stock is owned by a variety of institutional and retail investors. Top institutional investors include EPIQ Capital Group LLC (13.23%), Capital World Investors (11.67%), BlackRock Inc. (4.43%), Geode Capital Management LLC (1.10%), Citadel Advisors LLC (0.00%) and Burleson & Company LLC (0.00%). Company insiders that own Cortexyme stock include Casey Lynch, Christopher P Lowe, David Lamond, Epiq Capital Group, Llc, Leslie Holsinger, Margaret Mcloughlin, Michael J Detke and Stephen S Dominy.
View institutional ownership trends for Cortexyme.

Which major investors are selling Cortexyme stock?

CRTX stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, The Manufacturers Life Insurance Company , Rafferty Asset Management LLC, Robertson Stephens Wealth Management LLC, Cherry Creek Investment Advisors Inc., Royal Bank of Canada, Letko Brosseau & Associates Inc., and California State Teachers Retirement System. Company insiders that have sold Cortexyme company stock in the last year include Casey Lynch, Christopher P Lowe, Leslie Holsinger, Margaret Mcloughlin, and Michael J Detke.
View insider buying and selling activity for Cortexyme or view top insider-selling stocks.

Which major investors are buying Cortexyme stock?

CRTX stock was acquired by a variety of institutional investors in the last quarter, including EPIQ Capital Group LLC, Capital World Investors, Burleson & Company LLC, Caption Management LLC, Jane Street Group LLC, UBS Group AG, Pura Vida Investments LLC, and BlackRock Inc.. Company insiders that have bought Cortexyme stock in the last two years include David Lamond, Epiq Capital Group, Llc, and Stephen S Dominy.
View insider buying and selling activity for Cortexyme or or view top insider-buying stocks.

How do I buy shares of Cortexyme?

Shares of CRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cortexyme's stock price today?

One share of CRTX stock can currently be purchased for approximately $12.03.

How much money does Cortexyme make?

Cortexyme has a market capitalization of $359.43 million. The biopharmaceutical company earns $-76.85 million in net income (profit) each year or ($2.94) on an earnings per share basis.

How many employees does Cortexyme have?

Cortexyme employs 38 workers across the globe.

When was Cortexyme founded?

Cortexyme was founded in 2012.

What is Cortexyme's official website?

The official website for Cortexyme is www.cortexyme.com.

Where are Cortexyme's headquarters?

Cortexyme is headquartered at 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Cortexyme?

Cortexyme's mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company can be reached via phone at (650) 910-5717 or via email at [email protected].